Late-onset NMOSD patients see worse recovery, faster disability
A study linked late-onset neuromyelitis optica spectrum disorder to worse recovery from relapses and faster disability progression.| Neuromyelitis News
A study linked late-onset neuromyelitis optica spectrum disorder to worse recovery from relapses and faster disability progression.| Neuromyelitis News
Since her NMOSD diagnosis, columnist Jennifer V. has found routines crucial for distinguishing between bad days and signs of a flare-up.| Neuromyelitis News
Symptoms of late-onset NMOSD, occurring in patients over 50, may look like those of a stroke and can delay proper diagnosis and treatment.| Neuromyelitis News
Regular rituximab treatment in neuromyelitis optica spectrum disorder resulted in less disability and fewer relapses, per a real word study.| Neuromyelitis News
A new AI model that analyzes images of the eye can help accurately identify neuromyelitis optica spectrum disorder (NMOSD), a study shows.| Neuromyelitis News
Columnist Jennifer V. says she's learned a valuable lesson about coping with chronic illness by leaning into advocacy, rest, and community.| Neuromyelitis News
Most neuromyelitis optica spectrum disorder patients experience impaired sleep and worse disability relative to healthy people, per a study.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients on Enspryng remain free from relapses after six months, a real-world study in Japan shows.| Neuromyelitis News
Higher levels of the signaling molecule CXCL13 detected in the blood and CSF fluid of NMOSD patients were accompanied by worse disability.| Neuromyelitis News
NMOSD is among autoimmune disease risk factors, with patients at about nine times the risk of developing another condition, per a study.| Neuromyelitis News
Even though it's hard, columnist Jennifer V. hopes to be patient enough to outlast current health and professional struggles.| Neuromyelitis News
As columnist Jennifer van Amerom celebrates her daughter's 10th birthday, she reflects on the risks and challenges of NMO and pregnancy.| Neuromyelitis News
For columnist Jennifer V., telehealth appointments have made care more accessible, but some things just can't be done virtually, she says.| Neuromyelitis News
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
Understanding the body’s limits is key to conserving energy, writes columnist Jennifer V., who prioritizes her daily tasks with rest in mind.| Neuromyelitis News
Stressors drain energy that's already limited by NMOSD, says columnist Jennifer V., who shares how she's surviving the storms of life.| Neuromyelitis News
A recent increase in her NMOSD pain prompts columnist Jennifer V. to try acupuncture again, for the first time since her diagnosis.| Neuromyelitis News
The platelet-to-lymphocyte ratio may be used as a biomarker of disability severity in people with NMOSD, a study found.| Neuromyelitis News
Columnist Jennifer V. explains what "bed rotting" is and how it can be useful for NMOSD patients who need rest and recovery to avoid flares.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Living with NMOSD and its resulting disability can make it hard to find and keep employment, a new U.S. study highlights.| Neuromyelitis News
Depression, anxiety, and sleep disturbances are common among patients with neuromyelitis optica spectrum disorder, a new meta-analysis shows.| Neuromyelitis News
Columnist Candice Galvan shares how she came to realize that to better care for her daughter, she needed to protect her own mental health.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
NMOSD may begin to manifest as hard-to-treat nausea, vomiting, or hiccups — a condition called area postrema syndrome — delaying a diagnosis.| Neuromyelitis News
NMOSD patients who have had only one relapse tend to underestimate their future relapse risk, but this pattern changes with more relapses, a study finds.| Neuromyelitis News
Taking ginseng tablets twice a day for three months lessened fatigue in people with NMOSD, a placebo-controlled Phase 3 trial found.| Neuromyelitis News
What others may see as mood swings, columnist Jennifer van Amerom argues, are often reactions to trauma or treatment.| Neuromyelitis News
Neuromyelitis optica spectrum disorder patients whose first symptoms affect the brainstem are often misdiagnosed and have more relapses, a study finds.| Neuromyelitis News
With optic neuritis symptoms lingering despite treatment, columnist Jennifer van Amerom is trying to listen to what her body tells her.| Neuromyelitis News
After a series of plasma exchange sessions, columnist Jennifer van Amerom is hoping her vision fully returns to normal.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
Career changes, new home hunts, and symptom flares are a lot to handle, says columnist Jennifer van Amerom, who's juggling life and NMOSD.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News
Uplizna safely provided sustained disease control for NMOSD patients, according to final data from a Phase 2/3 clinical trial.| Neuromyelitis News
